Intensity-modulated radiotherapy for sinonasal teratocarcinosarcoma

Peng, Gang; Yang, Ke; Wang, Tao; Feng, Yiming; Li, Yuehua; Wu, Gang

doi:10.1007/s11596-011-0691-x

Cited by 10 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…and Peng et al . have utilized IMRT with good effect, with no recurrence at 2 and 3.5 years respectively [10, 11]. Our case supports the use of IMRT given the excellent outcome in our patient with minimal side effects 2 years post-radiotherapy.…”

Section: Discussionsupporting

confidence: 77%

Sinonasal teratocarcinosarcoma: a case report

et al. 2017

View full text Add to dashboard Cite

BackgroundSinonasal teratocarcinosarcoma is a rare and aggressive malignancy with histological features of both carcinosarcoma and teratoma. The optimal management of this malignancy is unclear, with most patients being managed by a combination of surgery and radiotherapy.Case presentationWe describe an 83-year-old white woman with sinonasal teratocarcinosarcoma of her left nasal cavity treated with surgical debulking initially with radiological evidence of residual disease which was treated with radiotherapy (60 Gy in 30 fractions). A follow-up examination at 2 years showed no evidence of recurrence.ConclusionsIn cases of sinonasal teratocarcinosarcoma with residual disease post-surgery, radiotherapy alone can be an effective option.

show abstract

Section: Discussionsupporting

confidence: 77%

Sinonasal teratocarcinosarcoma: a case report

et al. 2017

View full text Add to dashboard Cite

show abstract

“…All these patients showed no further evidence of disease, with the longest follow-up at 372 months. 1 Similarly, Peng et al 29 reported on one patient who, after surgery plus radiation therapy, showed no recurrence or metastasis at up to 3.5 years after treatment. Takasaki et al 10 also reported on one patient whose follow-up examination at close to 3.5 years after surgery plus radiation therapy revealed no evidence of recurrence or metastasis.…”

Section: Discussionmentioning

confidence: 92%

Sinonasal Teratocarcinosarcoma

et al. 2012

View full text Add to dashboard Cite

The goal of this study was to assess the pathological and differential diagnoses of sinonasal teratocarcinosarcoma (SNTCS) in order to ultimately improve the diagnosis and treatment of this rare disease. Data from 2 cases of sinonasal teratocarcinosarcoma from the Wuxi People's Hospital (China) were analyzed. The clinical presentation for these patients consisted of nasal obstruction, epistaxis, and headache. On further physical examination, the presence of a polypoid mass was identified and, despite surgery and radiotherapy, both cases experienced recurrence. Histologically, the tumors showed a heterogeneous mixture of components from the 3 germ layers, primitive neuroepithelial elements, diagnostic immature squamous cell nests (clear cell nests), and various epithelial and mesenchymal components. Staining of the different germ layers corresponded with the appropriate immune markers. In case 1, the postradiotherapy resection specimen was completely dominated by a mature teratoma, with a complete absence of the corresponding adenocarcinoma and fibrosarcoma components. To date, this is the first study describing this composition within an SNTCS recurrent tumor. In summary, SNTCS is a rare tumor characterized by the presence of benign and malignant epithelial, mesenchymal, and dysembryomal components. Owing to its heterogeneous histologic appearance, adequate sampling and recognition of all SNTCS components are needed for future diagnosis. Currently, surgical removal, postoperative radiotherapy, and a histology-specific multidrug chemotherapy appear to be the best therapeutic approach. Future individualized therapy may also hold promise.

show abstract

“…A total of 62 original articles and two review articles meeting inclusion criteria were reported in the literature from 1977–2018 and included in the study, representing a total of 127 unique patients (Figure 1). 1–64 In addition to these reported cases, we also present two new cases of SNTCS treated at our institution with review of imaging, pathology and treatment outcome.…”

Section: Methodsmentioning

confidence: 96%

Treatment of Sinonasal Teratocarcinosarcoma: A Systematic Review and Survival Analysis

Chapurin

Totten

Morse

et al. 2020

Am J Rhinol�Allergy

View full text Add to dashboard Cite

Background Sinonasal teratocarcinosarcoma (SNTCS) is a rare malignancy of the anterior skull base with only 127 cases described in the English literature. Given the rarity of this tumor, new cases and analysis of published reports may assist in future management of SNTCS. Objectives 1) Describe findings from a systematic review of all available literature for malignant SNTCS including the clinical presentation, treatment modalities and outcomes. 2) Present two new cases of this rare anterior skull base tumor. 3) Compare treatment outcomes with respect to recurrence and mortality. Methods A systematic review of all English literature available in 2 comprehensive databases was conducted by two independent reviewers using PRISMA guidelines. 85 publications were identified. Each case was reviewed for demographics, treatment and survival, and aggregate treatment outcomes were compared using Kaplan-Meier analysis. Results A total of 64 articles meeting inclusion criteria were reported in the literature between 1977-2018. This represented a total of 127 patients, with a strong male predominance (83%) and mean age of 50 years (range 10–82). Mean follow-up was 21 months. Recurrence rate was 38%, with mean survival at 2 years of 55%. Almost all patients underwent surgery as a primary treatment modality (90%). The majority of cases were treated with multimodal therapy, with 55% receiving surgery and radiation and 20% receiving surgery with adjuvant chemoradiation. Kaplan-Meier analysis demonstrated a significant survival advantage for patients treated with combined therapy compared to surgery alone (p < 0.001) but did not show differences in recurrence (p = 0.085). Conclusion Two-year survival rates for SNTCS are 55%. Multimodality treatment outcomes appear to be superior to surgery alone based on the published data of this rare skull base tumor, although heterogeneity of treatment methods and reporting bias limits the generalizability of these findings.

show abstract

Intensity-modulated radiotherapy for sinonasal teratocarcinosarcoma

Cited by 10 publications

References 21 publications

Sinonasal teratocarcinosarcoma: a case report

Sinonasal teratocarcinosarcoma: a case report

Sinonasal Teratocarcinosarcoma

Treatment of Sinonasal Teratocarcinosarcoma: A Systematic Review and Survival Analysis

Contact Info

Product

Resources

About